News & Insights (Healthcare)

InFocus: Life Sciences & Healthcare e-newsletter - January 2012

Welcome to the January issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at: ...

InFocus: Life Sciences & Healthcare e-newsletter - October 2011

Welcome to the October issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look ...

Advocate General's Opinion in SPC referral - infringement test rejected

As previously reported in our e-newsletters, InFocus - January 2011 and InFocus - October 2010, there have been a number of ...

InFocus: Life Sciences & Healthcare e-newsletter - July 2011

Welcome to the July issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at: ...

Negative and zero term SPCs OK says Advocate General

Merck & Co Inc v Deutsches Patent- und Markenamt (Case C-125/10) In his opinion on 9 June 2011, Advocate General Yves Bot ...

Informal consultation on the UK bolar and research exemptions

In its Plan for Growth published in March, the UK Government committed to ensure that the intellectual property system in the UK ...

UK healthcare reforms and the "Plan for Growth"

Improved healthcare means opportunities for life sciences and healthcare companies Successive UK governments have recognised ...

Taylor Wessing's Healthcare Group shortlisted for Legal Advisor of the Year at the Independent Healthcare Awards 2011

You never give me your money: Competition law, damages actions, and the healthcare sector

Public healthcare bodies that have suffered loss as a result of competition law infringements should consider ‘follow on’ damages ...

InFocus: Life Sciences & Healthcare e-newsletter - January 2011

Welcome to the January 2011 edition of InFocus, the Life Sciences and Healthcare newsletter. This month we discuss: Sold Out - ...

More heartburn for the pharma sector

The European Commission has escalated its crackdown on the pharma sector, conducting dawn raids yesterday on the originator ...

InFocus - Life Sciences & Healthcare e-newsletter - October 2010

Welcome to the October 2010 edition of InFocus, the Life Sciences and Healthcare newsletter. This month we discuss: Developing ...

InFocus - Life Sciences & Healthcare e-newsletter - July 2010

In the July issue of InFocus we discuss: Centralised procedure: guidance on duplicate marketing authorisations KREMEZIN and ...

Taylor Wessing advises Myotec Therapeutics on £5.6m funding round

Leading law firm Taylor Wessing has advised Myotec Therapeutics Ltd, the Cambridge based speciality pharmaceutical company, on ...

Generic Substitution - UK Department of Health Consultation

The UK government announced plans to introduce generic substitution in the Pharmaceutical Price Regulation Scheme (PPRS) 2009. On ...

InFocus - Life Sciences & Healthcare e-newsletter - January 2010

Life Sciences & Healthcare Update - December 2009

EU moves closer to Biosimilar antibodies

Patents and the EU medtech sector: a slumbering volcano

Tim Worden discusses the patent situation regarding medical devices in the EU in this article written by Faraz Kermani for the ...

Taylor Wessing advises Health Investment Holdings Limited on multi-million pound fundraising

European law firm Taylor Wessing LLP has advised independent hospital operator Health Investment Holdings Limited (HIHL) on its ...

Commission consultation on the functioning of the Clinical Trials Directive

The European Commission has launched a public consultation to assess the functioning of the Clinical Trials Directive ...

InFocus - Life Sciences & Healthcare e-newsletter - October 2009

Welcome to the October 2009 issue of InFocus

InFocus - Life Sciences & Healthcare e-newsletter - July 2009

InFocus - Life Sciences & Healthcare e-newsletter - April 2009

Taylor Wessing LLP advises Oxford BioMedica on a new collaboration with Sanofi-Aventis

Leading law firm Taylor Wessing LLP has advised Oxford BioMedica (LSE: OXB) on the negotiation of a new collaboration to develop ...

InFocus - Life Sciences & Healthcare e-newsletter - January 2009

Happy New Year and welcome to the January 2009 issue of InFocus. If you have any comments on the contents or the format please ...

The Regulation of Advanced Therapies: Perspectives from the EU

Healthcare and beauty sector worst offenders in ASA survey

The MHRA Investigation into GSK's Reporting of Adverse Events in Seroxat Paediatric Clinical Trials

Work involving human tissue samples - a new era in the UK

Developments in European Clinical Trial Agreements

Can SPC's have a zero or negative term?

Taylor Wessing advises Innate Pharma on the in-licence of a phase 1 monoclonal antibody from Novo Nordisk

Taylor Wessing's Life Sciences & Healthcare Group has advised Innate Pharma (IPH) on an agreement with Novo Nordisk, in which ...